PL3746106T3 - Inhibitory obojętnej endopeptydazy (nep) i ludzkiej rozpuszczalnej endopeptydazy (hsep) do profilaktyki i leczenia chorób oczu - Google Patents

Inhibitory obojętnej endopeptydazy (nep) i ludzkiej rozpuszczalnej endopeptydazy (hsep) do profilaktyki i leczenia chorób oczu

Info

Publication number
PL3746106T3
PL3746106T3 PL19747023.0T PL19747023T PL3746106T3 PL 3746106 T3 PL3746106 T3 PL 3746106T3 PL 19747023 T PL19747023 T PL 19747023T PL 3746106 T3 PL3746106 T3 PL 3746106T3
Authority
PL
Poland
Prior art keywords
endopeptidase
hsep
nep
prophylaxis
inhibitors
Prior art date
Application number
PL19747023.0T
Other languages
English (en)
Inventor
Christopher Turski
Original Assignee
Christopher Turski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Christopher Turski filed Critical Christopher Turski
Publication of PL3746106T3 publication Critical patent/PL3746106T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D267/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02Seven-membered rings
    • C07D267/08Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D281/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02Seven-membered rings
    • C07D281/04Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL19747023.0T 2018-01-31 2019-01-31 Inhibitory obojętnej endopeptydazy (nep) i ludzkiej rozpuszczalnej endopeptydazy (hsep) do profilaktyki i leczenia chorób oczu PL3746106T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL424452A PL424452A1 (pl) 2018-01-31 2018-01-31 Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
PCT/PL2019/000012 WO2019151882A1 (en) 2018-01-31 2019-01-31 Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of eye diseases

Publications (1)

Publication Number Publication Date
PL3746106T3 true PL3746106T3 (pl) 2024-06-24

Family

ID=67478423

Family Applications (2)

Application Number Title Priority Date Filing Date
PL424452A PL424452A1 (pl) 2018-01-31 2018-01-31 Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
PL19747023.0T PL3746106T3 (pl) 2018-01-31 2019-01-31 Inhibitory obojętnej endopeptydazy (nep) i ludzkiej rozpuszczalnej endopeptydazy (hsep) do profilaktyki i leczenia chorób oczu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL424452A PL424452A1 (pl) 2018-01-31 2018-01-31 Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu

Country Status (16)

Country Link
US (1) US20210046097A1 (pl)
EP (1) EP3746106B1 (pl)
KR (1) KR102867067B1 (pl)
CN (2) CN118948867A (pl)
CA (1) CA3088966C (pl)
ES (1) ES2983982T3 (pl)
HR (1) HRP20240728T1 (pl)
HU (1) HUE067550T2 (pl)
IL (1) IL275984B2 (pl)
MX (1) MX2020007989A (pl)
PL (2) PL424452A1 (pl)
RS (1) RS65651B1 (pl)
RU (1) RU2758771C1 (pl)
TW (1) TWI762760B (pl)
WO (1) WO2019151882A1 (pl)
ZA (1) ZA201905959B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL424453A1 (pl) 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)
KR102647920B1 (ko) 2021-10-13 2024-03-13 영남대학교 산학협력단 거짓비늘 녹내장 바이오 마커
CN117100845A (zh) * 2022-10-24 2023-11-24 景泽生物医药(合肥)股份有限公司 重组人奥克纤溶酶在制备治疗脉络膜血管疾病药物中的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19510566A1 (de) 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19750002A1 (de) 1997-11-12 1999-05-20 Solvay Pharm Gmbh Phosphonsäure-substituierte Benzazepinon-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
BR9908566A (pt) * 1998-03-05 2000-11-21 Senju Pharma Co Composição farmacêutica para profilaxia e terapia de doenças associadas a citopatia do tecido do fundo ocular
WO2002094176A2 (en) * 2001-05-18 2002-11-28 Solvay Pharmaceuticals Gmbh Use of compounds with combined nep/mp-inhibitory activity on the preparation of medicaments
BR0306701A (pt) 2002-01-16 2004-12-28 Solvay Pharm Bv Composto, sal do composto, sal de cálcio, método de preparação de um sal, composição farmacêutica, método de preparação de uma composição, e, uso de um sal
AR038681A1 (es) 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
WO2004062692A1 (en) 2003-01-13 2004-07-29 Solvay Pharmaceuticals B.V. Formulation of poorly water-soluble active substances
CL2004000545A1 (es) 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
SA04250283B1 (ar) * 2003-09-26 2008-05-26 سولفاي فارماسيتيكالز جي أم بي أتش مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid
EP1673107B1 (en) * 2003-10-10 2008-03-26 Solvay Pharmaceuticals GmbH Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker
US7232813B2 (en) 2004-01-12 2007-06-19 Solvay Pharmaceuticals B.V. Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders
CN101076339B (zh) * 2004-01-12 2011-02-09 索尔瓦药物有限公司 用于预防和治疗神经变性疾病的中性内肽酶(NEP)和人可溶内肽酶(hSEP)抑制剂
CA2626446A1 (en) * 2005-11-07 2007-05-18 Irm Llc Compounds and compositions as ppar modulators
EP3292868A1 (en) * 2009-08-24 2018-03-14 Stealth Peptides International, Inc. Methods and compositions for preventing or treating opthalmic conditions

Also Published As

Publication number Publication date
RU2758771C1 (ru) 2021-11-01
WO2019151882A4 (en) 2019-09-26
IL275984B1 (en) 2025-04-01
CN118948867A (zh) 2024-11-15
EP3746106C0 (en) 2024-03-27
TW201934536A (zh) 2019-09-01
CN111757750A (zh) 2020-10-09
IL275984B2 (en) 2025-08-01
ES2983982T3 (es) 2024-10-28
PL424452A1 (pl) 2019-08-12
IL275984A (en) 2020-08-31
KR20200116145A (ko) 2020-10-08
ZA201905959B (en) 2021-07-28
HRP20240728T1 (hr) 2024-08-30
EP3746106B1 (en) 2024-03-27
EP3746106A1 (en) 2020-12-09
US20210046097A1 (en) 2021-02-18
CA3088966C (en) 2025-06-03
MX2020007989A (es) 2020-09-09
RS65651B1 (sr) 2024-07-31
TWI762760B (zh) 2022-05-01
KR102867067B1 (ko) 2025-10-01
HUE067550T2 (hu) 2024-10-28
WO2019151882A1 (en) 2019-08-08
CA3088966A1 (en) 2019-08-08
EP3746106A4 (en) 2021-11-03

Similar Documents

Publication Publication Date Title
IL276383B1 (en) Treatment of ophthalmological diseases
SG11202101503RA (en) Combinations for treatment of nash/nafld and related diseases
SG11202102820VA (en) Ophthalmic composition for treatment of dry eye disease
EP3820500A4 (en) USE OF BCL6 INHIBITORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
IL277557A (en) Self-assembling peptidomimetics and peptidomimetics for the treatment of eye diseases
IL287802A (en) Preparations and methods for the treatment of eye diseases
IL279851A (en) Preparations and methods for treating diseases or conditions related to inflammasome
ZA201905959B (en) Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of eye diseases
GB201805100D0 (en) Treatment of sarcopenic diseases
EP3675889A4 (en) ANGIO -3 FOR THE TREATMENT OF ANGIOGENIC RETINAL DISEASES
IL290880A (en) Treatment of symptoms induced by the menstrual cycle
IL269698B (en) Methods for preventing or treating eye diseases
IL280952A (en) Methods and drug compounds for the treatment of ophthalmic diseases
CA3266235A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISEASES
SG11202004940VA (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
EP3993833A4 (en) Compositions and methods for treating eye diseases
IL282898A (en) Ophthalmic compounds and methods for treating skin and eye diseases
SMT202100070T1 (it) Complesso e composizioni per il trattamento di affezioni oculari e cutanee
IL280588A (en) Ophthalmic compositions and methods for treating eye problems and skin diseases
PL3797771T3 (pl) Rebamipid do stosowania w zapobieganiu i leczeniu celiakii
HK40079917A (en) Method and use of pnpp-19 for preventing and treating eye diseases
IL275994A (en) Human neutral endopeptidase and soluble endopeptidase inhibitors to reduce harmful effects of organ hypoperfusion
GB201909438D0 (en) Treatment of diseases
HK40056006A (en) Methods and compositions for drugs to treat ophthalmic diseases
GB201904764D0 (en) Treatment of ophthalmological conditions